100 filings
Page 2 of 5
8-K/A
69wk9hpoge96c 8wt
12 May 23
Changes in Registrant's Certifying Accountant
4:05pm
8-K/A
7zqrvnetm3ofo5 uav6
27 Apr 23
Changes in Registrant's Certifying Accountant
8:23am
8-K
1ri c011c4
13 Mar 23
Regulation FD Disclosure
7:51am
8-K
gp4g1w
6 Mar 23
Changes in Registrant's Certifying Accountant
5:07pm
8-K
j1dd n4ri
27 Feb 23
Genprex, Inc. Announces $4 Million
4:38pm
8-K
78172bc
22 Feb 23
Departure of Directors or Certain Officers
7:01am
8-K
4wfdrpw61 re7nu
6 Jan 23
Regulation FD Disclosure
4:35pm
8-K
0al45jjqnkurbk
5 Jan 23
Entry into a Material Definitive Agreement
4:40pm
8-K
4c3g1g4813nha849 4wf
16 Dec 22
Other Events
5:37pm
8-K
j0fo8ev
28 Nov 22
Entry into a Material Definitive Agreement
8:33am
8-K
haaigi8rvdf ifo
21 Nov 22
Regulation FD Disclosure
6:08am
8-K
zbrbsf0
18 Nov 22
Entry into a Material Definitive Agreement
4:22pm
8-K
jiz9 ff9woweg
21 Oct 22
Regulation FD Disclosure
4:14pm
8-K
wll4yg0
11 Oct 22
Regulation FD Disclosure
7:36am
8-K
xqyzw qczmygurz77n
19 Aug 22
Other Events
5:42pm
8-K
si7wyl
24 Jun 22
Submission of Matters to a Vote of Security Holders
5:01pm
8-K
v1f5k 2z2
5 May 22
Genprex Issues Shareholder Letter and Provides 2022 Corporate Update
8:30am
8-K
gjw0 wsh83ry
27 Apr 22
Regulation FD Disclosure
4:13pm
8-K
ukvtidieaj7ea
31 Mar 22
Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial
7:06am
8-K
cexrvbdikyk8vxc86wj
2 Mar 22
Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of
8:00am